June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Visual Acuity Outcomes in Patients Undergoing Epiretinal Membrane (ERM) and Internal Limiting Membrane (ILM) Peel With and Without Intraoperative Intraocular Triamcinolone
Author Affiliations & Notes
  • Shawn Agee
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX
  • Robert Wang
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX
  • Richard Winslow
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX
  • Footnotes
    Commercial Relationships Shawn Agee, None; Robert Wang, None; Richard Winslow, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3324. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shawn Agee, Robert Wang, Richard Winslow; Visual Acuity Outcomes in Patients Undergoing Epiretinal Membrane (ERM) and Internal Limiting Membrane (ILM) Peel With and Without Intraoperative Intraocular Triamcinolone. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3324.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine if those who underwent vitrectomy for idiopathic ERM with peeling ILM along with administration of intravitreal triamcinolone resulted in improved final visual acuity outcomes compared to those not receiving intraocular triamcinolone at the end of the case.

 
Methods
 

A retrospective review of medical records for those who underwent vitrectomy with ERM and ILM peeling. Patients included had an idiopathic ERM, vision worse than or equal to 20/60, and returned for at least 12 months of follow up postoperatively. Patients with visual acuity better than 20/60, insufficient follow up, previous vitrectomy, or secondary ERM were excluded from the study. The injection group received intravitreal injections of 0.1cc triamcinolone (Kenalog-40; Bristol Myers Squibb, Princeton, NJ) with the supernatant removed at the end of the case for biologic purposes, where as the control group did not receive any intravitreal steroids. Statistical analysis was performed using independent sample T-tests as well as Mann-Whitney U-tests using MedCalc Software 12.2.1.0 (Mariakerke, Belgium). P values of less than 0.05 were considered statistically significant.

 
Results
 

Fifty-eight eyes of 58 patients met the inclusion criteria. The injection group contained 27 eyes and the control group had 31 eyes. There were no statistically significant differences among the preoperative demographics between the two groups. The preoperative average visual acuity in the injection group was 0.66 logMAR, 0.56 logMAR at 1 month, 0.53 logMAR at 3 months, 0.49 logMAR at 6 months, and 0.38 logMAR at 12 months. The baseline/preoperative average visual acuity in the control group was 0.64 logMAR, 0.56 logMAR at 1 month, 0.49 logMAR at 3 months, 0.44 logMAR at 6 months, and 0.40 logMAR at 12 months. Analysis of the data shows that there was no statistically significant difference in the visual acuity at the 12 month endpoint, P=0.8.

 
Conclusions
 

Surgery for epiretinal membrane has been the treatment of choice since the 1980’s, but new techniques and medical adjuvants have allowed for better outcomes, both anatomically and functionally. Further studies looking at higher intraocular steroid concentrations or perhaps sustained release inserts of steroids may provide better final visual acuity outcomes in those undergoing epiretinal membrane removal.

     
Keywords: 585 macula/fovea • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×